HANGZHOU, ZHEJIANG, CHINA, January 16, 2026 /EINPresswire.com/ -- The pharmaceutical industry is undergoing a period of ...

The track by which API manufacturing processes are prepared for commercial use is comparable to overlapping integrative process evaluations at commercial scale. This ensures the process is ...

RICHMOND, Va., January 14, 2026 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced a major advancement in AI-driven Active ...

Enveda has been using AI to power its drug discovery platform for several years. The company injected $230 million into ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...

DUBLIN, May 10, 2021 /PRNewswire/ -- The "Global Active Pharmaceutical Ingredient Market (2020-2025) by Type, Molecule, Product Type, Formulation Type, Manufacturing Type, Synthesis Type, Drug Type, ...

TOKYO, October 22, 2015 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today the decision to construct a new plant for manufacturing antibody active pharmaceutical ingredients (API) ...

Technological innovations throughout the past several decades have transformed the pharmaceutical manufacturing process from traditional batch production to ...

−CDMO with a Six Decades-Long Reputation for Quality and Service Doubles Its Capacity to Take on New Development Projects− MORTON GROVE, Ill.--(BUSINESS WIRE)--Regis Technologies, Inc. today announced ...

"We are very excited to transition this fully-integrated API Pharmaceutical site, with its substantial reaction capacity, site infrastructure and attractive location, we are confident in the potential ...

Get 30% Off All Global Market Reports With Code ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors” - The Business Research Company LONDON, GREATER LONDON, UNITED ...

Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...